SecProbe.io

CORRESP
1
filename1.htm

Document

April 27, 2026

VIA EDGAR

Division of Corporation Finance

Office of Life Sciences

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Lauren Hamill

Re: Veradermics, Incorporated

 Registration Statement on Form S-1

 File No. 333-295356

 Acceleration Request

 Requested Date: April 29, 2026

 Requested Time: 4:00 P.M. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Veradermics, Incorporated (the “Company”) for acceleration of the effective time of the above-referenced Registration Statement, requesting effectiveness as of 4:00 P.M., Eastern Time, on April 29, 2026, or at such later time as the Company or its outside counsel, Ropes & Gray LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.

Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

[Signature Page Follows]

Very truly yours,

JEFFERIES LLC

LEERINK PARTNERS LLC

CITIGROUP GLOBAL MARKETS INC.

CANTOR FITZGERALD & CO.

As representatives of the underwriters

JEFFERIES LLC

By: /s/ Jack Fabbri

Name: Jack Fabbri

Title: Managing Director

LEERINK PARTNERS LLC

By: /s/ Dan Dubin, M.D.

Name: Dan Dubin, M.D.

Title: Vice Chairman, Head of Biopharma Investing Banking

CITIGROUP GLOBAL MARKETS INC.

By: /s/ John Whittaker

Name: John Whittaker

Title: Managing Director, Co-Head of NAM Biotech

CANTOR FITZGERALD & CO.

By: /s/ Jason Fenton

Name: Jason Fenton

Title: Managing Director, Co-Head Equity Capital Markets

[Signature Page to Underwriters’ Acceleration Request]

CORRESP
1
filename1.htm

Document

Veradermics, Incorporated

470 James St.

New Haven, CT 06513

April 27, 2026

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Lauren Hamill

Re: Veradermics, Incorporated

 Registration Statement on Form S-1 (File No. 333-295356)

 Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Veradermics, Incorporated, a Delaware corporation (the “Company”), hereby requests that the effective date for the registration statement referred to above be accelerated so that it will be declared effective at 4:00 p.m. Eastern Time on April 29, 2026, or as soon as possible thereafter. The Company hereby authorizes Zachary Blume and Nicholas Roper of Ropes & Gray LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.

Please call Zachary Blume or Nicholas Roper of Ropes & Gray LLP, counsel to the Company, at (617) 951-7663 or (617) 951-7116 as soon as the registration statement has been declared effective.

[Signature page follows]

Very truly yours,

VERADERMICS, INCORPORATED

By: /s/ Reid Waldman, M.D.

Name: Reid Waldman, M.D.

Title: Chief Executive Officer

[Signature Page to Acceleration Request]

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 7, 2026

Reid Waldman
Chief Executive Officer
Veradermics, Incorporated
470 James St.
New Haven, CT 06513

 Re: Veradermics, Incorporated
 Draft Registration Statement on Form S-1
 Submitted April 6, 2026
 CIK No. 0001827635
Dear Reid Waldman:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Lauren Hamill at 303-844-1008 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Nicholas Roper
</TEXT>
</DOCUMENT>